Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostata-neoplasmen - endokrine therapie - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische mittel - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. weitere informationen zum status des humanen epidermalen wachstumsfaktor-rezeptors 2 (her2) finden sie in abschnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. weitere informationen zum her2-status finden sie in abschnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dr. falk pharma gmbh (3076297) - zäpfchen - 4 mg

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

janssen-cilag gmbh (8009839) - epoetin alfa - injektionslösung - teil 1 - injektionslösung; epoetin alfa (26243) 0,336 milligramm

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pfizer pharma gmbh (8075658) - epirubicinhydrochlorid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; epirubicinhydrochlorid (22966) 50 milligramm

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

winthrop arzneimittel gmbh (8050629) - oxaliplatin - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; oxaliplatin (29849) 5 milligramm

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

actavis group ptc ehf. (8092378) - carboplatin - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; carboplatin (23168) 10 milligramm

Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunsuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis-arthritiscosentyx, allein oder in kombination mit methotrexat (mtx), ist indiziert zur behandlung der aktiven psoriasis-arthritis bei erwachsenen patienten, wenn die antwort zur vorherigen krankheitsmodifizierenden anti-rheumatischen droge (dmard) therapie unzureichend. axiale spondyloarthritiden (axspa)ankylosierende spondylitis (as, röntgenologische axiale spondyloarthritiden)cosentyx ist indiziert für die behandlung des aktiven morbus bechterew bei erwachsenen, die geantwortet haben, die unzureichend auf eine konventionelle therapie. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - etoricoxib - filmtablette - teil 1 - filmtablette; etoricoxib (30163) 30 milligramm

Ġermanja - Ġermaniż - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - etoricoxib - filmtablette - teil 1 - filmtablette; etoricoxib (30163) 120 milligramm